TG Therapeutics | TGTX - Interest Expense On Debt


TG Therapeutics reported $6.72M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Alaunos Therapeutics USD 0 0 Dec/2023
Amgen USD 653M 32M Dec/2025
Ardelyx USD 5.8M 784K Sep/2025
Arrowhead Research USD 21.69M 2.69M Sep/2025
Bayer EUR 762M 267M Sep/2025
Biogen USD 72.6M 12.6M Jun/2025
Corcept Therapeutics USD 823.61M 21.88M Sep/2025
Dynavax Technologies USD 1.64M 2K Sep/2025
Gilead Sciences USD 254M 6M Jun/2025
J&J USD 18M 290M Sep/2025
Novartis USD 281M 8M Sep/2025
PTC Therapeutics USD 2.64B 2.61B Sep/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
TG Therapeutics USD 6.72M 4K Sep/2025
Vertex Pharmaceuticals USD 3.3M 400K Sep/2025